Investment firms ARCH Venture Partners and Monograph Capital led a $120m funding round in Human Immunology Biosciences, a clinical-stage biotechnology company, with participation from Jeito Capital. "We know the power of precision medicine to achieve better results for patients, and HI-Bio is the first company to combine that approach with a focus on the latest in genetics and immunology for immune-mediated diseases," Paul Berns, ARCH Ventures Managing Director.